December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Enrique Grande: Pre-treatment metastatic biopsy by Niklas Klümper et al.
Nov 12, 2024, 16:41

Enrique Grande: Pre-treatment metastatic biopsy by Niklas Klümper et al.

Enrique Grande, Head of Oncology at MD Anderson Cancer Center, shared a post on X about a recent paper by Niklas Klümper, Senior Urology Consultant at the University Medical Center Bonn, published in Nature Reviews Urology:

“Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer.”

Authors: Niklas Klümper, Alexander Cox, Gottfrid Sjödahl, Florian Roghmann, Christian Bolenz, Arndt Hartmann, Viktor Grünwald, Bishoy Faltas, Michael Hölzel and Markus Eckstein.

Enrique Grande: Pre-treatment metastatic biopsy by Niklas Klümper et al.

More posts featuring Enrique Grande.

Enrique Grande, MD, PhD, MSc, is an Associate Professor at Francisco de Vitoria University. He is also an Adjunct Professor at the GU Medical Oncology Department and the Head of Oncology at MD Anderson Cancer Center.

Grande specializes in researching genitourinary and endocrine tumors and actively collaborates in developing the Translational Research and Early Drug Development Unit.

He founded the Spanish Group for Research on Orphan and Uncommon Tumors (GETHI) and serves on the Directory Board of the Spanish Task Force Group for NETs (GETNE). Dr. Grande edits several international journals and has participated in recent neuroendocrine tumor trials that led to the approval of new drugs in this field.

Niklas Klümper, MD, is a senior urology consultant specializing in genitourinary (GU) oncology and an advanced clinician-scientist at the University Medical Center Bonn (UKB), supported by the BMBF-funded ACCENT program.

He leads a translational uro-oncology research group that bridges the Department of Urology and the Institute of Experimental Oncology.

His research focuses on improving treatment response predictions for targeted therapies, developing personalized treatment strategies, and conducting clinical trials to enhance outcomes for patients with uro-oncological diseases.